Intradermal or intravenous administration typically requires 1–2 hours; patients often resume light activity same-day. Mild localised inflammation or fatigue within 24–48 hours is commonly reported. No extended downtime is expected. However, onset of any symptomatic benefit is gradual, unfolding over weeks rather than days. Immediate post-procedure monitoring protocols differ between clinics.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
Съм ли кандидат? → · Menopause & Hormonal Health: full overview → · Цена Менопауза и хормонално здраве → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка